Retroauricular subperiosteal vs systemic intravenous glucocorticoid administration on efficacy and blood glucose in diabetic patients with sudden deafness

Table 1 The two groups exhibit comparability in baseline data, n (%)

	Observation group (n = 66)	Control group (n = 62)	χ2	P value
Age, years old			0.183	0.669
≤ 60	38 (57.58)	38 (61.29)
> 60	28 (42.42)	24 (38.71)
Sex			0.32	0.572
Male	46 (69.70)	46 (74.19)
Female	20 (30.30)	16 (25.81)
Body mass index, kg/m²			0.183	0.669
≤ 24	28 (42.42)	24 (38.71)
> 24	38 (57.58)	38 (61.29)
Affected ear			0.125	0.724
Left	32 (48.48)	32 (51.61)
Right	34 (51.52)	30 (48.39)
History of smoking			0.847	0.357
With	7 (10.61)	10 (16.13)
Without	59 (89.39)	52 (83.87)
Dizziness			0.484	0.486
With	9 (13.64)	6 (9.68)
Without	57 (86.36)	56 (90.32)
Hypertension			1.002	0.317
With	20 (30.30)	24 (38.71)
Without	46 (69.70)	38 (61.29)
Hyperlipidemia			0.671	0.413
With	14 (21.21)	17 (27.42)
Without	52 (78.79)	45 (72.58)
Course of T2DM, years			0.426	0.514
≤ 5	25 (37.88)	27 (43.55)
> 5	41 (62.12)	35 (56.45)
Residence			0.157	0.692
Urban	55 (83.33)	50 (80.65)
Rural	11 (16.67)	12 (19.35)

T2DM: Type 2 diabetes mellitus.

Table 2 The observation group shows significantly superior therapeutic efficacy than the control group, n (%)

	Observation group (n = 66)	Control group (n = 62)	χ2	P value
Cure	20 (30.30)	16 (25.81)
Marked effectiveness	26 (39.39)	18 (29.03)
Effectiveness	14 (21.21)	13 (20.97)
Ineffectiveness	6 (9.09)	15 (24.19)
Total effectiveness	60 (90.91)	47 (75.81)	5.317	0.021

Table 3 The observation group is significantly lower than the control group in the incidence of adverse reactions, n (%)

	Observation group (n = 66)	Control group (n = 62)	χ2	P value
Dizziness	3 (4.55)	4 (6.45)
Nausea	1 (1.52)	3 (4.84)
Insomnia	1 (1.52)	3 (4.84)
Eye swelling and pain	0 (0.00)	4 (6.45)
Total adverse reactions	5 (7.58)	14 (22.58)	5.694	0.017

Table 4 Course of type 2 diabetes mellitus and therapeutic method are independent risk factors for therapeutic efficacy, n (%)

	Ineffective (n = 21)	Non-ineffective (n = 107)	Univariate analysis		Multivariate analysis
			OR	P value	OR	P value
Age, years old			0.565 (0.217-1.453)	0.234
≤ 60	10 (47.62)	66 (61.68)
> 60	11 (52.38)	41 (38.32)
Sex			0.974 (0.358-2.943)	0.960
Male	15 (71.43)	77 (71.96)
Female	6 (28.57)	30 (28.04)
BMI, kg/m²			0.530 (0.178-1.415)	0.224
≤ 24	6 (28.57)	46 (42.99)
> 24	15 (71.43)	61 (57.01)
Affected ear			1.121 (0.437-2.903)	0.811
Left	11 (52.38)	53 (49.53)
Right	10 (47.62)	54 (50.47)
History of smoking			1.701 (0.439-5.499)	0.399
With	4 (19.05)	13 (12.15)
Without	17 (80.95)	94 (87.85)
Dizziness			1.319 (0.280-4.675)	0.690
With	3 (14.29)	12 (11.21)
Without	18 (85.71)	95 (88.79)
Hypertension			1.952 (0.746-5.072)	0.167
With	10 (47.62)	34 (31.78)
Without	11 (52.38)	73 (68.22)
Hyperlipidemia			0.974 (0.296-2.766)	0.962
With	5 (23.81)	26 (24.30)
Without	16 (76.19)	81 (75.70)
Course of T2DM, years			0.197 (0.044-0.626)	0.013	0.171 (0.038-0.557)	0.008
≤ 5	3 (14.29)	49 (45.79)
> 5	18 (85.71)	58 (54.21)
Residence			0.647 (0.220-2.177)	0.448
Urban	16 (76.19)	89 (83.18)
Rural	5 (23.81)	18 (16.82)
Therapeutic method			0.313 (0.105-0.835)	0.026	0.267 (0.086-0.738)	0.014
Retroauricular subperiosteal injection of glucocorticoids injection	6 (28.57)	60 (56.07)
Systemic intravenous administration of glucocorticoids	15 (71.43)	47 (43.93)

BMI: Body mass index; OR: Odds ratio; T2DM: Type 2 diabetes mellitus.